Recursion Pharmaceuticals, Inc.

BMV:RXRX * Stock Report

Market Cap: Mex$87.1b

Recursion Pharmaceuticals Management

Management criteria checks 1/4

Recursion Pharmaceuticals' CEO is Chris Gibson, appointed in Nov 2013, has a tenure of 11.25 years. total yearly compensation is $8.61M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 1.79% of the company’s shares, worth MX$1.56B. The average tenure of the management team and the board of directors is 1.7 years and 10.5 years respectively.

Key information

Chris Gibson

Chief executive officer

US$8.6m

Total compensation

CEO salary percentage6.5%
CEO tenure11.3yrs
CEO ownership1.8%
Management average tenure1.7yrs
Board average tenure10.5yrs

Recent management updates

No updates

Recent updates

No updates

CEO Compensation Analysis

How has Chris Gibson's remuneration changed compared to Recursion Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$378m

Jun 30 2024n/an/a

-US$375m

Mar 31 2024n/an/a

-US$354m

Dec 31 2023US$9mUS$561k

-US$328m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$260m

Mar 31 2023n/an/a

-US$249m

Dec 31 2022US$6mUS$498k

-US$239m

Sep 30 2022n/an/a

-US$247m

Jun 30 2022n/an/a

-US$234m

Mar 31 2022n/an/a

-US$212m

Dec 31 2021US$674kUS$485k

-US$186m

Sep 30 2021n/an/a

-US$147m

Jun 30 2021n/an/a

-US$124m

Mar 31 2021n/an/a

-US$99m

Dec 31 2020US$3mUS$270k

-US$87m

Compensation vs Market: Chris's total compensation ($USD8.61M) is above average for companies of similar size in the MX market ($USD1.20M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Gibson (41 yo)

11.3yrs

Tenure

US$8,613,208

Compensation

Dr. Christopher C. Gibson, Ph.D. also known as Chris, is Director of Cellino Biotech, Inc. from October 2024. Dr. Gibson is a Co-Founder of Recursion Pharmaceuticals Inc and serves as its Chief Executive O...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Gibson
Co-Founder11.3yrsUS$8.61m1.79%
MX$ 1.6b
Dean Li
Co-Founder & Independent Director11.3yrsUS$300.25k0.81%
MX$ 701.4m
Blake Borgeson
Co-Founder & Director12.1yrsUS$292.74k1.79%
MX$ 1.6b
David Mauro
Chief Medical Officer1.7yrsUS$4.53m0.014%
MX$ 11.9m
Ben Taylor
CFO & President of Recursion UKless than a yearno data0.017%
MX$ 14.5m
Kristen Rushton
Chief Operating Officerless than a yearno datano data
Kevin Leggat
Vice President of Finance & Accountingno datano datano data
Benjamin Mabey
Chief Technology Officer5.1yrsno datano data
David Hallett
Chief Scientific Officerless than a yearno datano data
Jared Allenbach
Senior Director of Investor Relations2.8yrsno datano data
Nathan Hatfield
Chief Legal Officer & General Counsel1.3yrsno datano data
Erica Fox
Chief People and Impact Officerless than a yearno datano data

1.7yrs

Average Tenure

47yo

Average Age

Experienced Management: RXRX *'s management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Christopher Gibson
Co-Founder11.3yrsUS$8.61m1.79%
MX$ 1.6b
Dean Li
Co-Founder & Independent Director11.3yrsUS$300.25k0.81%
MX$ 701.4m
Blake Borgeson
Co-Founder & Director12.1yrsUS$292.74k1.79%
MX$ 1.6b
Najat Khan
Chief R&D Officerless than a yearno data0.0013%
MX$ 1.2m
Robert Lollini
Member of Business Advisory Panel10.3yrsno datano data
H. Fell
Member of Business Advisory Panel10.7yrsno datano data
Joseph Miletich
Chairman of Therapeutics Advisory Board3.6yrsno datano data
Robert Hershberg
Independent Chairman4.9yrsUS$302.74k0.0098%
MX$ 8.5m
Zachary Bogue
Independent Director6.5yrsUS$21.25k0.0024%
MX$ 2.1m
Anne Carpenter
Member of Scientific and Technical Advisory Board10.8yrsno datano data
Kirk Thomas
Member of Scientific & Technical Advisory Board10.8yrsno datano data
Zavain Dar
Independent Director8.4yrsUS$307.74k0.024%
MX$ 21.0m

10.5yrs

Average Tenure

60yo

Average Age

Experienced Board: RXRX *'s board of directors are seasoned and experienced ( 10.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 11:50
End of Day Share Price 2025/02/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recursion Pharmaceuticals, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gal MundaBerenberg
Gaurav GoparajuBerenberg
Alec StranahanBofA Global Research